Interchangeable insulins - New pathways for safe, effective, affordable diabetes therapy

Mariana P. Socal; Jeremy A. Greene

doi:10.1056/NEJMp1916387

Interchangeable insulins - New pathways for safe, effective, affordable diabetes therapy

Mariana P. Socal, Jeremy A. Greene

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Draft FDA guidance would reduce barriers to marketing high-quality generic insulin in the United States by declaring that the evidence necessary for proving an insulin product "highly similar" to an existing product is sufficient for designating it as interchangeable.

Original language	English (US)
Pages (from-to)	981-983
Number of pages	3
Journal	New England Journal of Medicine
Volume	382
Issue number	11
DOIs	https://doi.org/10.1056/NEJMp1916387
State	Published - Mar 12 2020

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMp1916387

Cite this

@article{61334b4cdb4f4313bfe6513db785ac36,

title = "Interchangeable insulins - New pathways for safe, effective, affordable diabetes therapy",

abstract = "Draft FDA guidance would reduce barriers to marketing high-quality generic insulin in the United States by declaring that the evidence necessary for proving an insulin product {"}highly similar{"} to an existing product is sufficient for designating it as interchangeable.",

author = "Socal, {Mariana P.} and Greene, {Jeremy A.}",

year = "2020",

month = mar,

day = "12",

doi = "10.1056/NEJMp1916387",

language = "English (US)",

volume = "382",

pages = "981--983",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "11",

}

TY - JOUR

T1 - Interchangeable insulins - New pathways for safe, effective, affordable diabetes therapy

AU - Socal, Mariana P.

AU - Greene, Jeremy A.

PY - 2020/3/12

Y1 - 2020/3/12

N2 - Draft FDA guidance would reduce barriers to marketing high-quality generic insulin in the United States by declaring that the evidence necessary for proving an insulin product "highly similar" to an existing product is sufficient for designating it as interchangeable.

AB - Draft FDA guidance would reduce barriers to marketing high-quality generic insulin in the United States by declaring that the evidence necessary for proving an insulin product "highly similar" to an existing product is sufficient for designating it as interchangeable.

UR - http://www.scopus.com/inward/record.url?scp=85081895366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081895366&partnerID=8YFLogxK

U2 - 10.1056/NEJMp1916387

DO - 10.1056/NEJMp1916387

M3 - Review article

C2 - 32160658

AN - SCOPUS:85081895366

VL - 382

SP - 981

EP - 983

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -

Interchangeable insulins - New pathways for safe, effective, affordable diabetes therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this